Cargando…

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?

Primary effusion lymphoma (PEL) is a rare condition, which accounts for approximately 4% of all human immunodeficiency virus (HIV)-associated non-Hodgkin lymphomas. PEL has a predilection for body cavities and occurs in the pleural space, pericardium, and peritoneum. Without treatment, the median su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jessamy, Kegan, Ojevwe, Fidelis O., Doobay, Ravi, Naous, Rana, Yu, John, Lemke, Sheila M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943741/ https://www.ncbi.nlm.nih.gov/pubmed/27462227 http://dx.doi.org/10.1159/000446315

Ejemplares similares

Clostridium septicum: An Unusual Link to a Lower Gastrointestinal Bleed
por: Jessamy, Kegan, et al.
Publicado: (2016)

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023)

Complete Response to R-EPOCH in Primary Cardiac Lymphoma
por: Anand, Kartik, et al.
Publicado: (2019)

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
por: Vassilakopoulos, T., et al.
Publicado: (2022)

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma
por: Ratner, L, et al.
Publicado: (2016)

Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement
por: Kojima, Minoru, et al.
Publicado: (2020)

Radiation therapy in primary mediastinal large B‐cell lymphoma treated with DA‐R‐EPOCH
por: Gentille, Cesar, et al.
Publicado: (2020)

The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH
por: Liang, Jin-Hua, et al.
Publicado: (2019)

P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
por: Vassilakopoulos, T., et al.
Publicado: (2022)

Is indwelling pleural catheter placement worthwhile for pleural effusion after lung resection?
por: Leung, Jackson Ka-Chun, et al.
Publicado: (2023)

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707
por: Maeda, Yoshinobu, et al.
Publicado: (2017)

Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
por: Ratner, Lee, et al.
Publicado: (2015)

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
por: Melani, Christopher, et al.
Publicado: (2018)

P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Endoscopic Glucocorticoid Injection for the Treatment of a Refractory Benign Esophageal Stenosis in a Patient With Plummer-Vinson Syndrome
por: Jessamy, Kegan, et al.
Publicado: (2023)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wilson, Wyndham H., et al.
Publicado: (2021)

Primary percutaneous coronary intervention in nonagenarians: is it worthwhile?
por: Meah, Mohammed M. N., et al.
Publicado: (2021)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas
por: Kim, Yoonjung, et al.
Publicado: (2014)

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
por: Pejša, Vlatko, et al.
Publicado: (2017)

Is Angiosome-Guided Endovascular Therapy Worthwhile?
por: Hata, Yosuke, et al.
Publicado: (2019)

Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic
por: Wei, Chong, et al.
Publicado: (2021)

Primary Effusion Lymphoma Presenting As Parapneumonic Pleural Effusion
por: Gujarathi, Rahul, et al.
Publicado: (2022)

Indolent primary effusion lymphoma
por: Nagrale, Vidya, et al.
Publicado: (2020)

Infant cardiopulmonary resuscitation from the wheelchair. Is it feasible and worthwhile?
por: Barcala-Furelos, Roberto, et al.
Publicado: (2023)

The cubist epoch
por: Cooper, Douglas, 1911-1984
Publicado: (1970)

The Psychology of Epochs
Publicado: (1852)

Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
por: Morgenstern, Yael, et al.
Publicado: (2021)

Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma
por: Moodad, Sara, et al.
Publicado: (2020)

Is screening for colorectal cancer worthwhile?
por: Chamberlain, J.
Publicado: (1990)

Apprenticeship: a worthwhile option
por: Laëtitia Pedroso
Publicado: (2010)

Writing worthwhile behavioral objectives
por: Vargas, Julie S.
Publicado: (1972)

The fight against cancer: Is it worthwhile?
por: Barreto, Savio George, et al.
Publicado: (2015)

Travel Less. Make It Worthwhile.
por: Geitmann, Anja
Publicado: (2020)

Redo ventral rectopexy: is it worthwhile?
por: Laitakari, K. E., et al.
Publicado: (2020)

Diagnostic significance of adenosine deaminase in pleural effusate for primary effusion lymphoma–like lymphoma
por: Nakako, Soichiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_47apq76ck9i2d4ad7bftjfkbei